The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro.
The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro.
复制标题
DOI：
10.1016/j.antiviral.2020.104787
复制
发表时间：
2020-06-01
影响因子：
7.6
通讯作者：
Wagstaff, Kylie M
中科院分区：
文献类型：
--
作者：
Caly, Leon;Druce, Julian D;Wagstaff, Kylie M
尽管目前正在进行多项临床试验以测试可能的疗法，但全球对COVID-19爆发的反应主要限于监测/遏制。我们在此报告，伊维菌素，一种FDA批准的抗寄生虫药，先前在体外显示出具有广谱抗病毒活性，是病原病毒（SARS-CoV-2）的抑制剂，在SARS-CoV-2感染后2小时，单次添加到Vero-hSLAM细胞中，能够在48小时实现约5000倍的病毒RNA减少。因此，伊维菌素需要进一步研究其对人类的可能益处。
Although several clinical trials are now underway to test possible therapies, the worldwide response to the COVID-19 outbreak has been largely limited to monitoring/containment. We report here that Ivermectin, an FDA-approved anti-parasitic previously shown to have broad-spectrum anti-viral activity in vitro, is an inhibitor of the causative virus (SARS-CoV-2), with a single addition to Vero-hSLAM cells 2h post infection with SARS-CoV-2 able to effect ~5000-fold reduction in viral RNA at 48h. Ivermectin therefore warrants further investigation for possible benefits in humans.